Abstract
A subset of gastrointestinal neuroendocrine tumours (carcinoids and pancreatic endocrine tumours) show aggressive growth. Early identification of this subset is essential for management; however, clinical, laboratory and histologic features frequently fail to achieve this. Currently, there is an increased understanding of the molecular pathogenesis/changes in neuroendocrine tumours and this may identify important prognostic factors and possibly, new treatments. Recent findings and progress in this area are briefly reviewed in this article.
MeSH terms
-
Gastrinoma / genetics
-
Gastrinoma / metabolism
-
Gastrinoma / mortality
-
Gastrointestinal Neoplasms / genetics*
-
Gastrointestinal Neoplasms / metabolism
-
Gastrointestinal Neoplasms / mortality
-
Genes, Tumor Suppressor*
-
Humans
-
Immunohistochemistry
-
Mutation
-
Neuroendocrine Tumors / genetics*
-
Neuroendocrine Tumors / metabolism
-
Neuroendocrine Tumors / mortality
-
Oncogenes*
-
Platelet-Derived Growth Factor / metabolism*
-
Survival Rate
-
Transforming Growth Factor alpha / metabolism*
Substances
-
Platelet-Derived Growth Factor
-
Transforming Growth Factor alpha